Project Title: Pilot project to accelerate the evaluation of ASOs to treat Dup15q syndrome

Project Dates: 1/1/25 – 12/31/25

Grant: $50,000 (DREAM grant)

Summary: Dup15q syndrome symptoms are often more severe when extra gene copies are maternally inherited rather than paternally inherited. Since UBE3A is the only gene in the region expressed exclusively from maternal DNA, UBE3A overexpression is likely a driver of Dup15q syndrome pathophysiology. The proposed work will assess how reducing high Ube3a expression in a Dup15q syndrome mouse model could improve behavioral deficits. By using an antisense oligonucleotide (ASO), Dr. Judson’s pilot studies will provide valuable insight to the dosage, duration, and route of administration for a UBE3A gene therapy.

Dr. De Marco is an assistant professor of neuroscience in the Brain and Mind Research Institute at Weill Cornell Medical College. She earned her B.S. in molecular genetics and biotechnology from the University of Buenos Aires and her Ph.D. in neurobiology and behavior at Columbia University.

Project Title: An in vivo strategy to study the impact of GABRB3 mutations on the development of cortical circuits

Project Dates: 2024 – 2025

Grant: $25,000

The proposed experiments will assess the impact of high-risk ASD mutations at the human chromosome 15q locus on the maturation of GABAergic circuits. The work aims to uncover how early GABAergic dysfunction, including copy number variation at the critical region on 15q, leads to lasting neuropathologies such as Dup 15q syndrome. This project will further our understanding of how GABAergic activity affects early brain maturation during critical periods of development and how this process goes awry in neurodevelopmental disorders, leading to impaired behavior. Results will provide preliminary insight into how increased Gabrb3 manifests as Dup15q syndrome to assess its potential as a future drug target.

Jason Yi, PhD is an Assistant Professor of Neuroscience at Washington University School of Medicine. His research focuses on understanding the molecular pathways involved in nervous system development and function, particularly in the context of autism spectrum disorders (ASD).

Project Title: Deep phenotyping of mouse models of UBE3A gain-of-function

Project Dates: February 1, 2024 – January 31, 2025

Grant: $47,158.00 (Co-Funded by Dup15q Alliance and The Orphan Disease Center at Upenn)

Summary: Dup15q syndrome is caused by a duplication or triplication of maternal chromosome 15q11-13 whereas individuals with paternal duplications are typically developing. There are more than 20 genes within chromosome 15q11-13, but among them, Ube3a is the only gene expressed exclusively from the maternal allele in neurons. These observations strongly suggest that excessive UBE3A protein activity is the major driver of disease phenotypes in Dup15q syndrome. This proposal will perform deep phenotypic analysis of an allelic series of mice that possess gain-of-function mutations in Ube3a of increasing severity. By doing so, our study will identify specific phenotypes in mice that are caused by excessive UBE3A protein activity. These studies will provide valuable models and information that can be leveraged to design therapeutic strategies for this disorder.

 

Gilles Travé obtained a PhD in molecular biology and biochemistry from the University of Toulouse (France). After a post-doctoral work in structural biology at the EMBL-Heidelberg (Germany) he was appointed as a research scientist by the Centre National de la Recherche Scientifique (CNRS) to work at the Ecole Supérieure de Biotechnologie de Strasbourg (Université de Strasbourg, France). He currently leads a research team dedicated to structure-function studies on the E6 oncoproteins of human papillomaviruses (HPVs). After having struggled many years to solubilize E6 proteins, the team has solved the first structures of E6 proteins, free or in complex with several cellular targets, obtained several informations of E6 protein function, and is currently developing tools to analyze the structural basis of the large cellular interactome of these small viral proteins. Gilles Travé has published several articles dedicated to the analyzis and optimization of recombinant protein quality and he regularly teaches practical courses on this topic, in particular at the University of Bergen (Norway) where he is regularly invited as a visiting professor.

Grant: $100,000 annually ($200,000 total) * This research project is jointly funded by Dup15q Alliance and Angelman Syndrome Foundation.

 

Dr. Trave will study the interaction between UBE3A and HERC2 to regulate important genes for neurodevelopment and better understand how UBE3A and HERC2 work together.

This study aims to:

• Create the first 3D structure of full-length UBE3A with and without HERC2
• Determine the other proteins that interact with the UBE3A/HERC2 complex

This should help future studies better understand how UBE3A works with HERC2 to impact brain development.

Ype Elgersma is a professor at the Erasmus University Medical Center in Rotterdam, and the scientific director of the ENCORE Expertise Centre for Neurodevelopmental Disorders. His laboratory focuses on molecular and cellular mechanisms underlying neurodevelopmental disorders

Project Title: Characterization of a Novel Dup(Atp10a-Tub5gcp5) ‘Dup15q’ Mouse Model with Varying Levels of UBE3A

Project Dates: 2023 – 2024

Grant: $50,000

Dup15q syndrome is a neurodevelopmental disorder caused by duplications of a region on chromosome 15, often resulting in intellectual disability and intractable epilepsy. Recent findings indicate that the symptoms may be caused by an interaction of the UBE3A (Ubiquitin Protein Ligase 3A) gene with other genes in the duplicated region. However, the precise interaction between UBE3A and the other duplicated genes is unclear.  Dr. Elgersma’s team proposes to develop a new mouse model to study the interaction and dose effect of these genes. If successful, this project will generate a novel representative mouse model of Dup15q syndrome which will be an important tool to study the syndrome as well as to test potential therapies in the future.

The one-year grant is funded in partnership with CURE Epilepsy, whose portion is sponsored by the Robert Withrow Wier Fund.

Dr. Ben Philpot earned his Ph.D. in psychobiology from the University of Virginia in 1997. He performed a neuroscience postdoctoral fellowship in the laboratory of Dr. Mark Bear at Brown University and M.I.T., before coming to UNC in 2004. He is currently a Kenan Distinguished Professor in the Department of Cell Biology and Physiology, Associate Director of the UNC Neuroscience Center, and a member of the Neuroscience Curriculum and the Carolina Institute for Developmental Disabilities (CIDD). Dr. Philpot is the co-Director of a cross-disciplinary postdoctoral training grant for the CIDD.

Project Title:  Exploration of critical periods for UBE3A overexpression in Dup15q syndrome and ASD

Project Dates: 2019 – 2021

Grant: $50,000 annually ($100,000 total)

Abstract: Dup15q syndrome accounts for 1-3% of all autism spectrum disorders and carries significant risk for seizures, which can be lethal. Individuals with Dup15q inherit extra copies – usually 1 or 2 – of genes within the 1511.2- q13 chromosome region. It is unclear which of these contributes to the disorder, or how they increase risk for seizures, but UBE3A has emerged as a primary candidate gene. We will generate new mouse models for the study of    how extra UBE3A copies confer risk for seizures. Our mice will carry 1 or 2 extra Ube3a copies, mirroring the UBE3A overdosage observed in Dup15q. Using these models, we will study key aspects of seizure expression: 1) initial responses to  seizure-causing drugs (seizure threshold), (2) responses to repeated, recurrent seizures (epilepsy), and (3) lethality during seizures, which could help us to model sudden unexpected death in epilepsy (SUDEP), a serious risk for individuals with Dup15q. We will also perform electroencephalograpy (EEG) on our mice to determine if UBE3A overdosage produces changes in brain rhythms that are seen in the Dup15q population. Our project will yield insights into the relationship between a key Dup15q gene and the debilitating seizures plaguing individuals with the disorder, and in the process, provide outstanding training opportunities in seizure behavior and in vivo electrophysiology. Importantly, our models will be applicable to the study of any relevant Dup15q phenotypes, and they will feature reversible Ube3a overexpression, so that the therapeutic benefits of returning Ube3a to normal levels can be explored.

Dr. Charlotte DiStefano is a clinical psychologist with expertise in minimally verbal children with ASD and related neurodevelopmental disorders. She is a Clinical Instructor in Psychiatry and Biobehavioral Sciences.

After receiving a B.S. in Special Education from New York University and an Ed.M. in Mind Brain and Education from Harvard University, Dr. Charlotte Distefano received her Ph.D. in Psychological Studies in Education from UCLA. She completed her postdoctoral training at the UCLA Center for Autism Research and under the mentorships of Drs. Connie Kasari and Shafali Jeste. Before earning her Ph.D., Dr. DiStefano worked as a special education teacher with children with ASD, in both New York City and Los Angeles.

Clinically, Dr. DiStefano sees patients in the Child and Adult Neurodevelopmental Clinic, and the Developmental Neurogenetics Clinic. She provides assessment and evaluation of children with ASD and related neurodevelopmental disorders, as well as treatment consultations regarding language and communication development.

Grant: $25,000

Summary: This study will employ a telehealth model to conduct remote assessment of developmental and clinical characteristics of children with dup15q syndrome, and evaluate the feasibility, sensitivity and test-retest reliability of the measures. We will use the Parent-Administered NeuroDevelopmental Assessment Box (PANDABox), atelehealth-based assessment battery for children with rare syndromes, along with the Brief Observation of Social Communication Change (BOSCC). PANDABox integrates experimental methods (e.g. automated monitoring of heart rate, vocalizations) with parent-led between ages 2-10 (interstitial and isodicentric), who are ambulatory and use no or minimal spoken language. Participants will complete two initial remote assessment batteries, within one week of each other. These assessments will be used to examine test-retest reliability. Participants will then complete a third remote assessment battery, approximately 6 months later. This time point will be used to examine change over time in the experimental variables. Data from all three time points will be used to examine feasibility and tolerability of the experimental measures. Based on the funding provided, we will be able to create two PANDABox kits. We anticipate that the initial two time points will require the kits to be in use for three weeks (two allow the family to complete two assessment sessions), while the final time point will require the kits to be in use for two weeks. This timeline will allow us to collect and analyze data from 10 families within the funding period, which is sufficient to complete
the proposed pilot testing.